Business Milestones
2025.03.11
TAHO Pharmaceuticals to Present Cardiovascular Innovations at BIO Europe Spring 2025
Taipei — March 10, 2025
TAHO Pharmaceuticals announced that it will present at BIO Europe Spring 2025, taking place March 17-19, 2025, in Milan, Italy. The presentation is scheduled for Monday, March 17, 2025, at 14:15 CET on the Exhibit Hall Stage at the MiCo Milano Convention Centre.
The presentation will feature additional data from the completed pivotal trial of TAH3311, apixaban oral dissolving film, showcasing its role in the company’s innovative cardiovascular product portfolio. Additionally, company representatives will be available for one-on-one meetings throughout the conference to discuss potential partnerships and collaborations.
BIO Europe Spring is expected to attract more than 3,700 executives from biotech, pharmaceutical, and finance companies, facilitating over 20,000 one-on-one meetings. For those interested in scheduling a meeting with TAHO representatives, please contact the
Company directly at ir@tahopharma.com or use the conference’s meeting portal.
About TAHO Pharmaceuticals Ltd.
Founded in 2010, TAHO Pharmaceuticals Ltd. leverages its proprietary Transepithelial DeliverySystem (TDS) to overcome the limitations of existing drugs and develop innovative dosageforms for niche markets. The TDS platform combines advanced transdermal and transmucosal delivery technologies, enabling the development of unique dosage forms such as transdermal patches, ODF, and buccal films. TAHO’s diverse product portfolio spans a variety of therapeutic areas, including antithrombotic agents, opioid overdose antidotes, addiction treatments, pediatric ADHD, and chemotherapy-induced antiemetics. Among its notable achievements, TAH4411, an ODF for chemotherapy-induced nausea and vomiting, became the first product of its kind to receive regulatory approval and be commercialized in Japan.
Media Contact:
TAHO Pharmaceuticals
+886-2-2659-8515
ir@tahopharma.com
TAHO Pharmaceuticals announced that it will present at BIO Europe Spring 2025, taking place March 17-19, 2025, in Milan, Italy. The presentation is scheduled for Monday, March 17, 2025, at 14:15 CET on the Exhibit Hall Stage at the MiCo Milano Convention Centre.
The presentation will feature additional data from the completed pivotal trial of TAH3311, apixaban oral dissolving film, showcasing its role in the company’s innovative cardiovascular product portfolio. Additionally, company representatives will be available for one-on-one meetings throughout the conference to discuss potential partnerships and collaborations.
BIO Europe Spring is expected to attract more than 3,700 executives from biotech, pharmaceutical, and finance companies, facilitating over 20,000 one-on-one meetings. For those interested in scheduling a meeting with TAHO representatives, please contact the
Company directly at ir@tahopharma.com or use the conference’s meeting portal.
About TAHO Pharmaceuticals Ltd.
Founded in 2010, TAHO Pharmaceuticals Ltd. leverages its proprietary Transepithelial DeliverySystem (TDS) to overcome the limitations of existing drugs and develop innovative dosageforms for niche markets. The TDS platform combines advanced transdermal and transmucosal delivery technologies, enabling the development of unique dosage forms such as transdermal patches, ODF, and buccal films. TAHO’s diverse product portfolio spans a variety of therapeutic areas, including antithrombotic agents, opioid overdose antidotes, addiction treatments, pediatric ADHD, and chemotherapy-induced antiemetics. Among its notable achievements, TAH4411, an ODF for chemotherapy-induced nausea and vomiting, became the first product of its kind to receive regulatory approval and be commercialized in Japan.
Media Contact:
TAHO Pharmaceuticals
+886-2-2659-8515
ir@tahopharma.com